Divi's Laboratories Ltd (DIVISLAB)

Divi's Laboratories Ltd (DIVISLAB) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 226975.64 Cr. Figures below are as reported and are shown with their source and date.

Educational use only — GoQuant is a research tool. This page lists company facts only and is not a recommendation. Investment advice is provided by FINOME TECHNOLOGIES PVT LTD (AltQube), SEBI-registered Investment Adviser, registration no. INA000018373, under a signed advisory agreement and after a risk profile. Past performance is not indicative of future results.

Company profile

Sector
Pharmaceuticals
Industry
Pharmaceuticals & Biotechnology
Market cap (₹ Cr)
2,26,975.64

Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 16,543 full-time employees. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).

Source: finedge · as of 2026-09-29

Price, last year

Last close (₹): 9,162

Source: quantro_screener_metrics_job · as of 2026-10-22

Key figures

P/E
94.72
52-week high
9,740
52-week low
5,647.5
Revenue CAGR, 3 years (%)
10.78
Revenue CAGR, 5 years (%)
8.67
EPS CAGR, 3 years (%)
12.09
EPS CAGR, 5 years (%)
5.29

Source: quantro_screener_metrics_job · as of 2026-10-23

Annual summary

Year endedRevenue (₹ Cr)PAT (₹ Cr)EPS (₹)
Mar 202610,5602,56896.73
Mar 20259,3602,19182.53
Mar 20247,8451,60060.27
Mar 20237,767.511,823.3868.69
Mar 20228,959.832,960.45111.52

Source: finedge · as of 2026-07-21

Shareholding and promoter pledge

Promoter
51.88%
FII
20.29%
DII
19.22%
Public
8.6%
Promoter shares pledged
0%

Source: finedge · as of 2026-03-31

Similar companies

Source: quantro_company_profiles · as of 2026-10-23

Recent exchange filings

Source: nse · as of 2026-10-05

Frequently asked questions

What does Divi's Laboratories Ltd do?
Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 16,543 full-time employees. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).
Which sector is Divi's Laboratories Ltd in?
Divi's Laboratories Ltd is in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry.
What are Divi's Laboratories Ltd's latest annual revenue and profit?
For the year ended Mar 2026: revenue 10560.00 Cr, profit after tax 2568.00 Cr.
What is the promoter holding and pledge in Divi's Laboratories Ltd?
Promoter holding is 51.88%; pledged shares are 0.00% of the promoter holding.
Which companies are similar to Divi's Laboratories Ltd?
Companies in the same sector of similar size: Torrent Pharmaceuticals Ltd, Zydus Lifesciences Ltd, Cipla Ltd, Lupin Ltd, Mankind Pharma Ltd, Dr Reddy's Laboratories Ltd.
Want more history and detail? Create a free account for the full price history, quarterly statements, balance sheet and cash flow.

Figures computed 2026-10-23.